A Study of TG103 Injection in Type 2 Diabetes Subjects

A phase 2 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 240 participants.

Also called NCT05348122

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 240 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT05348122
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT05348122. Randomized; single masking; primary purpose treatment. Start 2022-06-15 (anticipated); primary completion 2023-11-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study of TG103 Injection in Type 2 Diabetes Subjects
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
TG103,Q2W
Intervention (Drug)
TG103,QW
Intervention (Drug)
Placebo,Q2W
Intervention (Drug)
Placebo,QW
Intervention (Drug)
Dulaglutide,QW
Lead sponsor
CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct05348122
Content hash
c68431633972f330d25e44f08e0950c2882844c959d345b250b9cade81cac85f